Enzon
Executive Summary
Begins marketing Adagen, an orphan drug used in the treatment of Severe Combined Immunodeficiency Disease (SCID), which is fatal if untreated. Adagen costs $2,200 per vial in the U.S. and $3,000 outside the country. The company says "the price is based on the cost of the raw materials used to manufacture the drug, monitoring patients and meeting quality control regulatory standards." National Organization for Rare Disorders (NORD) Executive Director Abbey Meyers defended Enzon's pricing of the drug: "Unlike the blockbuster drugs masquerading as 'orphans' to keep out competition and making hundreds of millions of dollars, Adagen is a true orphan drug." Adagen received orphan status in May 1984; Enzon filed the NDA in January 1988. The drug has been available at no charge since its approval in March. According to Enzon, about 40 cases of ADA-deficient SCID are diagnosed annually worldwide ("The Pink Sheet" March 26, T&G-1).
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.